10x Genomics (NASDAQ:TXG) Rating Lowered to Hold at Zacks Research

10x Genomics (NASDAQ:TXG) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Several other research firms also recently commented on TXG. Piper Sandler upped their price objective on shares of 10x Genomics from $15.00 to $19.00 and gave the company a “neutral” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research report on Tuesday, October 14th. Wall Street Zen raised shares of 10x Genomics from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Morgan Stanley lowered their price target on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 12th. Finally, UBS Group lifted their price objective on shares of 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $14.88.

10x Genomics Trading Up 1.2%

Shares of 10x Genomics stock traded up $0.21 during trading on Monday, hitting $16.80. 122,770 shares of the stock were exchanged, compared to its average volume of 3,224,952. The company has a fifty day moving average price of $12.93 and a 200-day moving average price of $11.91. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -27.06 and a beta of 2.13. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $17.70.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. The business had revenue of $149.00 million during the quarter, compared to analysts’ expectations of $142.50 million. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.10x Genomics’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.30) earnings per share. 10x Genomics has set its Q4 2025 guidance at EPS. Equities research analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insider Activity at 10x Genomics

In related news, CEO Serge Saxonov sold 9,348 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the sale, the chief executive officer directly owned 945,892 shares of the company’s stock, valued at $13,043,850.68. This trade represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Benjamin J. Hindson sold 7,486 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the sale, the insider owned 440,888 shares in the company, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 39,149 shares of company stock valued at $539,865 over the last three months. 10.03% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC lifted its stake in shares of 10x Genomics by 8.1% in the second quarter. ARK Investment Management LLC now owns 13,892,103 shares of the company’s stock worth $160,871,000 after acquiring an additional 1,046,390 shares during the period. Vanguard Group Inc. increased its position in shares of 10x Genomics by 6.7% during the third quarter. Vanguard Group Inc. now owns 13,274,332 shares of the company’s stock worth $155,177,000 after buying an additional 834,272 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in 10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after acquiring an additional 4,987,195 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in shares of 10x Genomics by 12.2% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,017,963 shares of the company’s stock worth $69,688,000 after acquiring an additional 654,597 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. boosted its position in shares of 10x Genomics by 12.1% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 6,009,653 shares of the company’s stock valued at $69,532,000 after purchasing an additional 646,997 shares in the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.